1. Standard BMI thresholds associated with greater risk of diabetes varied across 57 low- and middle-income countries depending on geographical ...
1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of ...
1. Sotagliflozin treatment was shown to increase the days-alive-and-out-of-hospital compared to placebo in patients with type 2 diabetes and heart ...
1. Widespread diabetes screening helps to identify asymptomatic patients with preserved renal function and low diabetes-associated cardiovascular risk. 2. New ...
2 Minute Medicine is pleased to announce that we are launching Wellness Check, a new series dedicated to exploring new ...
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients ...
![Type I diabetes not associated with early menopause [OVADIA study]](https://2minutemedicine-wpengine.netdna-ssl.com/wp-content/uploads/2014/12/diabetes1_edited-350x250.jpg)
1. Compared to patients of European descent, poorer health outcomes were seen among Māori and Pacific New Zealanders with type ...
1. 10-year remission rates were significantly higher for Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD) than medical therapy. 2. ...
1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.